Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers

Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medical virology 2021-03, Vol.93 (3), p.1766-1769
Hauptverfasser: Capetti, Amedeo F., Borgonovo, Fabio, Morena, Valentina, Lupo, Angelica, Cossu, Maria Vittoria, Passerini, Matteo, Dedivitiis, Gianfranco, Rizzardini, Giuliano
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1769
container_issue 3
container_start_page 1766
container_title Journal of medical virology
container_volume 93
creator Capetti, Amedeo F.
Borgonovo, Fabio
Morena, Valentina
Lupo, Angelica
Cossu, Maria Vittoria
Passerini, Matteo
Dedivitiis, Gianfranco
Rizzardini, Giuliano
description Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.
doi_str_mv 10.1002/jmv.26485
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7891345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2481910066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</originalsourceid><addsrcrecordid>eNp1kctKAzEYhYMotl4WvoAMuHIxmmSSzMxGkOIVRbDabcjk0klpJzWZqt35CD6jT2JqtejCTf7A-f6TQw4AewgeIQjx8WjyfIQZKega6CJYsrSEOVoHXYgISxlDtAO2QhhBCIsS403QyXBRoKh2gerXzrcfb--t9pPENrWtbGtdkziT9E_v-1HpuUE8cVLNk3quvBvqJplq716t0nFjcQ82tLppk0YEN62FnzdDLcaJFN7bqO6ADSPGQe9-z23weH720LtMb-4urnqnN6mksKQpyTIpmVYCl6RipCKSkkxmxGhlsFYkN1IqxWhWGKmRoJhWEOaV0bIQBpV5tg1Olr7TWTXRSsZIXoz51NtJzMSdsPyv0tiaD90zz4sSZYRGg4NvA--eZjq0fORmvomZOSYFKuNvMxapwyUlvQvBa7N6AUG-KITHQvhXIZHd_x1pRf40EIHjJfBix3r-vxO_vh0sLT8B3mGbHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2481910066</pqid></control><display><type>article</type><title>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Capetti, Amedeo F. ; Borgonovo, Fabio ; Morena, Valentina ; Lupo, Angelica ; Cossu, Maria Vittoria ; Passerini, Matteo ; Dedivitiis, Gianfranco ; Rizzardini, Giuliano</creator><creatorcontrib>Capetti, Amedeo F. ; Borgonovo, Fabio ; Morena, Valentina ; Lupo, Angelica ; Cossu, Maria Vittoria ; Passerini, Matteo ; Dedivitiis, Gianfranco ; Rizzardini, Giuliano</creatorcontrib><description>Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.26485</identifier><identifier>PMID: 32881014</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Burning ; Carrier State - drug therapy ; Carrier State - virology ; Chemical agents ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - drug therapy ; Female ; Humans ; Hydrogen peroxide ; Hydrogen Peroxide - therapeutic use ; Male ; Middle Aged ; Mucosa ; nasopharingeal ; Nasopharynx - virology ; Oxidants - therapeutic use ; persistent ; Physicians ; Respiratory diseases ; SARS-CoV-2 - drug effects ; SARS-CoV-2 - isolation &amp; purification ; SARS‐CoV‐2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Short Communication ; Short Communications ; Side effects ; swab ; Treatment Outcome ; Viral diseases ; Virology ; Virus Shedding - drug effects ; Viruses</subject><ispartof>Journal of medical virology, 2021-03, Vol.93 (3), p.1766-1769</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC</rights><rights>2020 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</citedby><cites>FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</cites><orcidid>0000-0003-4633-1035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.26485$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.26485$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32881014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Capetti, Amedeo F.</creatorcontrib><creatorcontrib>Borgonovo, Fabio</creatorcontrib><creatorcontrib>Morena, Valentina</creatorcontrib><creatorcontrib>Lupo, Angelica</creatorcontrib><creatorcontrib>Cossu, Maria Vittoria</creatorcontrib><creatorcontrib>Passerini, Matteo</creatorcontrib><creatorcontrib>Dedivitiis, Gianfranco</creatorcontrib><creatorcontrib>Rizzardini, Giuliano</creatorcontrib><title>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Burning</subject><subject>Carrier State - drug therapy</subject><subject>Carrier State - virology</subject><subject>Chemical agents</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogen peroxide</subject><subject>Hydrogen Peroxide - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mucosa</subject><subject>nasopharingeal</subject><subject>Nasopharynx - virology</subject><subject>Oxidants - therapeutic use</subject><subject>persistent</subject><subject>Physicians</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2 - drug effects</subject><subject>SARS-CoV-2 - isolation &amp; purification</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Short Communication</subject><subject>Short Communications</subject><subject>Side effects</subject><subject>swab</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Virology</subject><subject>Virus Shedding - drug effects</subject><subject>Viruses</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctKAzEYhYMotl4WvoAMuHIxmmSSzMxGkOIVRbDabcjk0klpJzWZqt35CD6jT2JqtejCTf7A-f6TQw4AewgeIQjx8WjyfIQZKega6CJYsrSEOVoHXYgISxlDtAO2QhhBCIsS403QyXBRoKh2gerXzrcfb--t9pPENrWtbGtdkziT9E_v-1HpuUE8cVLNk3quvBvqJplq716t0nFjcQ82tLppk0YEN62FnzdDLcaJFN7bqO6ADSPGQe9-z23weH720LtMb-4urnqnN6mksKQpyTIpmVYCl6RipCKSkkxmxGhlsFYkN1IqxWhWGKmRoJhWEOaV0bIQBpV5tg1Olr7TWTXRSsZIXoz51NtJzMSdsPyv0tiaD90zz4sSZYRGg4NvA--eZjq0fORmvomZOSYFKuNvMxapwyUlvQvBa7N6AUG-KITHQvhXIZHd_x1pRf40EIHjJfBix3r-vxO_vh0sLT8B3mGbHQ</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Capetti, Amedeo F.</creator><creator>Borgonovo, Fabio</creator><creator>Morena, Valentina</creator><creator>Lupo, Angelica</creator><creator>Cossu, Maria Vittoria</creator><creator>Passerini, Matteo</creator><creator>Dedivitiis, Gianfranco</creator><creator>Rizzardini, Giuliano</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4633-1035</orcidid></search><sort><creationdate>202103</creationdate><title>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</title><author>Capetti, Amedeo F. ; Borgonovo, Fabio ; Morena, Valentina ; Lupo, Angelica ; Cossu, Maria Vittoria ; Passerini, Matteo ; Dedivitiis, Gianfranco ; Rizzardini, Giuliano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Burning</topic><topic>Carrier State - drug therapy</topic><topic>Carrier State - virology</topic><topic>Chemical agents</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogen peroxide</topic><topic>Hydrogen Peroxide - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mucosa</topic><topic>nasopharingeal</topic><topic>Nasopharynx - virology</topic><topic>Oxidants - therapeutic use</topic><topic>persistent</topic><topic>Physicians</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2 - drug effects</topic><topic>SARS-CoV-2 - isolation &amp; purification</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Short Communication</topic><topic>Short Communications</topic><topic>Side effects</topic><topic>swab</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Virology</topic><topic>Virus Shedding - drug effects</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Capetti, Amedeo F.</creatorcontrib><creatorcontrib>Borgonovo, Fabio</creatorcontrib><creatorcontrib>Morena, Valentina</creatorcontrib><creatorcontrib>Lupo, Angelica</creatorcontrib><creatorcontrib>Cossu, Maria Vittoria</creatorcontrib><creatorcontrib>Passerini, Matteo</creatorcontrib><creatorcontrib>Dedivitiis, Gianfranco</creatorcontrib><creatorcontrib>Rizzardini, Giuliano</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Capetti, Amedeo F.</au><au>Borgonovo, Fabio</au><au>Morena, Valentina</au><au>Lupo, Angelica</au><au>Cossu, Maria Vittoria</au><au>Passerini, Matteo</au><au>Dedivitiis, Gianfranco</au><au>Rizzardini, Giuliano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2021-03</date><risdate>2021</risdate><volume>93</volume><issue>3</issue><spage>1766</spage><epage>1769</epage><pages>1766-1769</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32881014</pmid><doi>10.1002/jmv.26485</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-4633-1035</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0146-6615
ispartof Journal of medical virology, 2021-03, Vol.93 (3), p.1766-1769
issn 0146-6615
1096-9071
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7891345
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
Antiviral Agents - therapeutic use
Burning
Carrier State - drug therapy
Carrier State - virology
Chemical agents
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - drug therapy
Female
Humans
Hydrogen peroxide
Hydrogen Peroxide - therapeutic use
Male
Middle Aged
Mucosa
nasopharingeal
Nasopharynx - virology
Oxidants - therapeutic use
persistent
Physicians
Respiratory diseases
SARS-CoV-2 - drug effects
SARS-CoV-2 - isolation & purification
SARS‐CoV‐2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Short Communication
Short Communications
Side effects
swab
Treatment Outcome
Viral diseases
Virology
Virus Shedding - drug effects
Viruses
title Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T12%3A38%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%E2%80%90term%20inhibition%20of%20SARS%E2%80%90CoV%E2%80%902%20by%20hydrogen%20peroxide%20in%20persistent%20nasopharyngeal%20carriers&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Capetti,%20Amedeo%20F.&rft.date=2021-03&rft.volume=93&rft.issue=3&rft.spage=1766&rft.epage=1769&rft.pages=1766-1769&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.26485&rft_dat=%3Cproquest_pubme%3E2481910066%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2481910066&rft_id=info:pmid/32881014&rfr_iscdi=true